CSIMarket Company Name, Ticker, Customers, else..
 
Diamedica Therapeutics Inc   (NASDAQ: DMAC)
 
Price: $6.4600 $-0.01 -0.155%
Day's High: $6.876999855041504 Week Perf: -4.3 %
Day's Low: $ 6.43 30 Day Perf: -4.3 %
Volume (M): 47,019 52 Wk High: $ 10.42
Volume (M$): $ 0 52 Wk Avg: $7.11
Open: $6.57 52 Wk Low: $5.24



 Market Capitalization (Millions $) 348
 Shares Outstanding (Millions) 54
 Employees 35
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -38
 Cash Flow (TTM) (Millions $) 1
 Capital Exp. (TTM) (Millions $) 0

Business Description


Diamedica Therapeutics Inc is a biopharmaceutical company that focuses on the development of innovative therapies for patients with neurological and cardiovascular diseases. The company aims to address unmet medical needs in these areas by leveraging their expertise in protein engineering and biotherapeutics. Their research and development efforts primarily involve the development of drugs that target specific disease mechanisms or pathways. Diamedica Therapeutics Inc is committed to improving patient outcomes and enhancing the quality of life for individuals suffering from these debilitating conditions.


   Company Address: 301 Carlson Parkway, Suite 210 Minneapolis 55305 MN
   Company Phone Number: 496-5454   Stock Exchange / Ticker: NASDAQ DMAC


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ARDX   -2.56%    
INVA   -3.93%    
ONC   -4.87%    
TEVA   -1.47%    
VRTX   -8.07%    
VTRS   -2.95%    
• View Complete Report
   



Business Update

DiaMedica Therapeutics Engaging with Investors While Navigating Market Performance Challenges

Published Tue, Sep 2 2025 1:12 PM UTC

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, is making noteworthy strides in its mission to develop innovative therapies for conditions such as preeclampsia, fetal growth restriction, and acute ischemic stroke. Recent developments at the company have positioned it in the spotlight, especially as it gears up to participate in the Can...
Business Update

DiaMedica Therapeutics Announces Closing of $30.1 Million Private Placement

Published Thu, Jul 24 2025 8:48 AM UTC

Strategic Advancements and Scientific Progress at DiaMedica Therapeutics: A Look at Recent Developments MINNEAPOLIS DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company at the forefront of innovating therapies for critical conditions like preeclampsia, fetal growth restriction, and acute ischemic stroke, has been making waves in the heal...
Business Update

DiaMedica Therapeutics Secures $30.1 Million through Private Placement While Navigating Financial Setbacks,

Published Thu, Jul 24 2025 4:35 AM UTC

DiaMedica Therapeutics Closes $30.1 Million Private Placement Amidst Financial Challenges DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company headquartered in Minneapolis, recently announced the successful closing of a $30.1 million private placement of common shares intended for accredited investors. The funding round involved the sale of ...
Business Update

Groundbreaking Progress in Preeclampsia Treatment DiaMedica Therapeutics Unveils Promising Phase 2 Results for DM199

Published Thu, Jul 17 2025 1:46 PM UTC

In a significant advancement for women s health, DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company based in Minneapolis, has reported compelling interim results from Part 1a of its Phase 2 clinical trial investigating DM199 (rinvecalinase alfa) for the treatment of preeclampsia. This interim analysis not only met but exceeded pre-specifie...
Business Update

Breaking Ground in Biopharmaceuticals DiaMedica Therapeutics to Spotlight Innovations at the 2025 Jefferies Global ...

Published Thu, May 22 2025 3:44 PM UTC

In an era marked by remarkable advancements in healthcare, one company is positioning itself at the forefront of biopharmaceutical innovation. DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical firm based in Minneapolis, is shaping the landscape of treatment for two critical medical conditions: preeclampsia and acute ischemic stroke. As part of th...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 9.08
PEG (TTM) -

Financial Strength Current
Quick Ratio 12.42
Working Capital Ratio 12.58
Leverage Ratio (MRQ) 0.17
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.74 $
Revenues (TTM) -
Cash Flow (TTM) 0.01 $
Cash 1.52 $
Book Value 0.71 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,072,600
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.